Innovative Targeted and Immune-Mediated Cancer Therapies

Pipeline

Developing first-in-class oral drug therapeutics with broad potential benefit for cancer patients

Learn more

Science

Thoughtful exploration of new and validated pathways to discover and develop novel therapeutics

Learn more

News

April 28, 2025
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

April 21, 2025
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

April 9, 2025
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Events

Tuesday, December 3RD, 2024 at 9:00 AM Eastern
Piper Sandler 36th Annual Healthcare Conference
Listen: Webcast

Thursday, June 20TH, 2024 at 8:30 AM Eastern
Amezalpat (TPST-1120) Global Randomized Phase 1b/2 Combination Study Update Call
Listen: Webcast
Download: Presentation [pdf]

Wednesday, October 11TH, 2023 at 8:30 AM Eastern
TPST-1120 Global Randomized Phase 1b/2 Combination Study Data Call
Listen: Webcast
Download: Presentation [pdf]